Simris Biologics selects Nuvisan as CRO for antibody-drug conjugate project

Simris Biologics, a biotech company based in Berlin, Germany, has selected Nuvisan, the Science CRO, to evaluate its proprietary microcystin payloads for antibody-drug conjugates (ADCs). This collaboration unites Simris’ unique cyanobacteria-derived technologies with our expertise in oncology drug discovery to accelerate advances in cancer therapy.